European Journal of Dermatology
MENUExcess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis Volume 22, issue 3, May-June 2012
Figures
Dermatology Unit,, Pediatric Dermatology Unit,
University of Padua
Via C. Battisti 206,
35128, Padova, Italy
- DOI : 10.1684/ejd.2012.1704
- Page(s) : 416-7
- Published in: 2012
ejd.2012.1704 Auteur(s) : Edoardo Zattra1, Anna Belloni Fortina2, Mauro Alaibac1 mauro.alaibac@unipd.it 1 Dermatology Unit, 2 Pediatric Dermatology Unit, University of Padua Via C. Battisti 206, 35128, Padova, Italy Eruption and/or excess of multiple melanocytic nevi has been reported to occur in patients treated with immunosuppressive drugs or chemotherapy [1]. Natalizumab (Tysabri™, Dompè Biogen) is a humanized monoclonal antibody against the cellular adhesion molecule alpha4-integrin, used to [...]